Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 7/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14405148 | 1.00 | CSF1R (0.56) | CSF1RAKR1C3HDAC1HDAC2HDAC3 | |
| SCHEMBL4333962 | 1.00 | CSF1R (0.56) | CSF1RAKR1C3HDAC1HDAC2HDAC3 | |
| SCHEMBL4333959 | 0.85 | CSF1R (0.57) | CSF1R | |
| SCHEMBL4196292 | 0.80 | CSF1R (0.54) | CSF1RHDAC1HDAC2HDAC3 | |
| SCHEMBL5650117 | 0.78 | CSF1R (0.39) | CSF1RAKR1C3GHSR | |
| SCHEMBL14405083 | 0.78 | CSF1R (0.39) | CSF1RAKR1C3GHSR | |
| SCHEMBL5650123 | 0.78 | CSF1R (0.39) | CSF1RAKR1C3GHSR | |
| SCHEMBL5650089 | 0.74 | L3MBTL1 (0.40) | CSF1RAKR1C3 | |
| SCHEMBL5650093 | 0.74 | L3MBTL1 (0.40) | CSF1RAKR1C3 | |
| SCHEMBL14404923 | 0.74 | L3MBTL1 (0.40) | CSF1RAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452996-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| EP-2021329-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-13 | — | — | EP | disclosed |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-9221797-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| US-8674100-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2014-03-18 | — | — | US | disclosed |
| EP-2687516-A1 | Inhibitors of C-FMS Kinase | Janssen Pharmaceutica N.V. (BE) | 2014-01-22 | — | — | EP | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CSF1R 58/4885AKR1C3 4230/4885HDAC1 2158/4885 |
| US-20140148448-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CSF1R 58/4885AKR1C3 4230/4885HDAC1 2158/4885 |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CSF1R 58/4885AKR1C3 4230/4885HDAC1 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.